Prevalence of and Risk Factors for Major Comorbidities of Systemic Lupus Erythematosus Using Data from a Multicenter Chinese Cohort Registry: A Cross-Sectional Study
Minhui Wang,Jiaxin Zhou,Feng Zhan,Hui Luo,Xinwang Duan,Cheng Zhao,Zhenbiao Wu,Hongbin Li,Min Yang,Qin Li,Jian Xu,Can Huang,Jiuliang Zhao,Qian Wang,Xiaomei Leng,Xinping Tian,Mengtao Li,Yan Zhao,Xiaofeng Zeng
DOI: https://doi.org/10.2139/ssrn.4176779
2022-01-01
SSRN Electronic Journal
Abstract:Background: Patients with systemic lupus erythematosus (SLE) are at high risk for cardiovascular disease (CVD), fragility fractures, and malignancy. However, data regarding these comorbidities among Chinese SLE patients are limited. We aimed to determine the prevalence of and risk factors for these major comorbidities in a large cohort of Chinese SLE patients.Methods: During this cross-sectional study, demographic, clinical, and common comorbidity profiles were obtained from the medical records of SLE patients enrolled in the Chinese SLE treatment and Research group (CSTAR) registry. Univariate and multivariate logistic regression analyses were performed to identify the possible risk factors related to the three major comorbidities.Results: A total of 38,105 SLE patients were included (92.2% women). The median age at registration was 34.0 years (interquartile range, 27.0–46.0 years). The prevalence rates of the three major comorbidities at baseline were as follows: CVD, 1.9% (95% confidence interval [CI]: 1.8%–2.0%); fragility fracture, 0.7% (95% CI: 0.6%–0.8%); and malignancy, 0.7% (95% CI: 0.6%–0.8%). In the multivariable-adjusted model, lupus anticoagulant, anticardiolipin antibody, anti-β2GP1 antibody, neuropsychiatric involvement, and hematological involvement were positively associated with CVD in SLE patients. Mucocutaneous manifestations, hyperimmunoglobulinemia, hypocomplementemia, anti-dsDNA, anti-Sm and anti-RNP antibody, and hydroxychloroquine therapy were negatively associated with CVD. The multivariate analysis revealed that age older than 50 years and hypocomplementemia were associated with fragility fractures and malignancy.Conclusion: CVD, fragility fractures, and malignancy commonly occur in SLE patients. These patients with traditional and SLE-related factors should be more carefully monitored for these major comorbidities.